DOCSLIB.ORG

Access Document

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Access Document BMJ Confidential: For Review Only Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors and Glucagon-Like Peptide-1 (GLP-1) receptor agonists for type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials Journal: BMJ Manuscript ID BMJ-2020-058523 Article Type: Research BMJ Journal: BMJ Date Submitted by the 17-May-2020 Author: Complete List of Authors: Palmer, Suetonia; University of Otago Christchurch, Medicine Tendal, Britta; Monash University, School of Public Health and Preventive Medicine Mustafa, Reem; University of Kansas School of Medicine, Internal Medicine, Division of Nephrology and Hypertension; McMaster University, Department of Health Research Methods, Evidence and Impact Vandvik, Per; Innlandet Hospital Trust-divisjon Gjøvik, Department of Medicine Li, Sheyu; Sichuan University, Department of Endocrinology and Metabolism, West China Hospital Hao, Qiukui; Sichuan University West China Hospital; McMaster University Department of Medicine, Department of Health Research Methods, Evidence and Impact Tunnicliffe, David; The University of Sydney, School of Public Health Ruospo, Marinella; University of Bari, Department of Emergency and Transplantation Natale, Patrizia; The University of Sydney, School of Public Health Saglimbene, Valeria; University of Bari, Department of Emergency and Organ Transplantation Nicolucci, Antonio; Center for Outcomes Research and clinical Epidemiology (CORESEARCH) Johnson, David; Translational Research Institute Tonelli, Marcello; University of Calgary, Cumming School of Medicine Rossi, Maria; Center for Outcomes Research and clinical Epidemiology Badve, Sunil; The George Institute for Global Health, UNSW Sydney; Department of Renal Medicine, St George Hospital Nadeau-Fredette, Annie-Claire; Universite de Montreal Faculte de medecine Burke, Michael; University of Queensland; Princess Alexandra Hospital, Faruque, Labib; University of Alberta Lloyd, Anita; University of Alberta Ahmad, Nasreen; University of Alberta Liu, Yuanchen; University of Alberta, Department of Medicine Tiv, Sophanny; University of Alberta Millard, Tanya; Monash University, School of Public Health and https://mc.manuscriptcentral.com/bmj Page 1 of 244 BMJ 1 2 3 Preventive Medicine 4 Gagliardi, Lucia; The Queen Elizabeth Hospital, Endocrine and Diabetes 5 Unit 6 Kolanu, Nithin; Garvan Institute of Medical Research 7 Barmanray, Rahul; The University of Melbourne, Department of Medicine 8 McMorrow, Rita; The University of Melbourne, Department of General 9 Practice Raygoza Cortez, Ana Karina; Universidad Autonoma de Nuevo Leon 10 Confidential:White, Heath; For Monash University Review Only 11 Chen, Xiangyang; Sichuan University 12 Zhou, Xu; Chinese evidence-based medicine center, West China hospital, 13 Sichuan University 14 Liu, Jiali; West China Hospital, Sichuan University, Chinese Evidence- 15 based Medicine Center 16 Flores Rodriguez, Andrea; Universidad Autonoma de Nuevo Leon Díaz Gonzalez-Colmenero , Alejandro; Universidad Autonoma de Nuevo 17 Leon 18 Wang, Yang; Sichuan University 19 Li, Ling; West China Hospital, Sichuan University, Chinese Evidence- 20 based Medicine Center 21 Suntanto, Surya; The University of Sydney, Charles Perkins Centre 22 Research and Education Hub Cesar Solis, Ricardo; Universidad Autonoma de Nuevo Leon 23 Díaz-González , Fernando; Universidad Autonoma de Nuevo Leon 24 Walsh, Michael; St. Joseph's Hospital, Division of Nephrology 25 Guyatt, Gordon; McMaster University 26 Strippoli, Giovanni; Universita degli Studi di Bari Dipartimento 27 Emergenza e Trapianti di Organi 28 diabetes, network meta-analysis, patient outcomes, mortality, SGLT-2 Keywords: 29 inhibitors, GLP-1 receptor agonists 30 31 32 33 Note: The following files were submitted by the author for peer review, but cannot be converted to PDF. 34 You must view these files (e.g. movies) online. 35 Appendix 2 SGLT2-I and GLP1RA NMA_2020.05.11.xlsx 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 https://mc.manuscriptcentral.com/bmj BMJ Page 2 of 244 1 2 3 4 Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors and Glucagon-Like Peptide- 5 6 1 (GLP-1) receptor agonists for type 2 diabetes: A systematic review and network meta- 7 8 analysis of randomised controlled trials 9 10 11 Authors 12 Confidential: For Review Only 13 Suetonia C. Palmer, nephrologist and professor1, Britta Tendal, living guidelines program 14 15 manager2 Reem A. Mustafa, nephrologist and methodologist3,4, Per Olav Vandvik, 16 17 18 physician and methodologist5, Sheyu Li, diabetologist and research fellow6,7, Qiukui Hao, 19 20 physician and visiting scholar8, David Tunnicliffe, research fellow9, Marinella Ruospo, 21 22 research fellow10, Patrizia Natale, PhD candidate9, Valeria Saglimbene, research fellow10, 23 24 25 Antonio Nicolucci, diabetologist and professor11, David W. Johnson, nephrologist12, 26 27 Marcello Tonelli, nephrologist13, Maria Chiara Rossi, epidemiologist11, Sunil V. Badve, 28 29 nephrologist14 Yeoungjee Cho, nephrologist12, Annie-Claire Nadeau-Fredette, 30 31 32 nephrologist15, Michael Burke, nephrologist16, Labib I Faruque, clinical assistant17, Anita 33 34 Lloyd, researcher17, Nasreen Ahmad, study coordinator17, Yuanchen Liu, researcher17, 35 36 Sophanny Tiv, health informatics programmer17, Tanya Millard, research fellow2, Lucia 37 38 Gagliardi, endocrinology specialist18, Nithin Kolanu, endocrinology trainee19, Rahul D 39 40 41 Barmanray, endocrinologist and PhD candidate20, Rita McMorrow, general practitioner and 42 43 PhD candidate21, Ana Karina Raygoza Cortez, research trainee22, Heath White, senior 44 45 research officer2, Xiangyang Chen, research fellow6, Xu Zhou, lecturer23, Jiali Liu, 46 47 48 researcher24, Andrea Flores Rodríguez, research trainee22, Alejandro Díaz González- 49 50 Colmenero, research trainee22 Yang Wang, researcher25, Ling Li, assistant professor24, 51 52 Surya Sutanto, research scientist26, Ricardo Solis, researcher22 Fernando Díaz González, 53 54 55 research trainee22 Michael T Walsh, nephrologist27 Gordon Guyatt,professor4, Giovanni 56 57 F.M. Strippoli, professor10 58 59 60 1 https://mc.manuscriptcentral.com/bmj Page 3 of 244 BMJ 1 2 3 Affiliations 4 5 6 1 Department of Medicine, University of Otago, Christchurch, New Zealand 7 2 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia 8 3 Department of Internal Medicine, Division of Nephrology and Hypertension, University of 9 Kansas, Kansas City, USA 10 4 Department of Health Research Methods, Evidence and Impact, McMaster University, 11 Hamilton, Canada 12 5 InstituteConfidential: of Health and Society, University For ofReview Oslo, Norway Only 13 14 6 Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, 15 China 16 7 Ninewells Hospital, University of Dundee 17 8 The Center for Gerontology and Geriatrics, West China Hospital, Sichuan University, China 18 9 Sydney School of Public Health, The University of Sydney, Sydney, Australia 19 10 Department of Emergency and Transplantation, University of Bari, Bari, Italy 20 11 Center for Outcomes Research and Clinical Epidemiology (CORESEARCH), Pescara, Italy 21 22 12 Department of Nephrology, Division of Medicine, University of Queensland at Princess 23 Alexandra Hospital, Woolloongabba, Australia 24 13 Cumming School of Medicine, University of Calgary, Calgary, Canada 25 14 The George Institute for Global Health, Sydney Australia 26 15 Department of Nephrology, Hôpital Maisonneuve-Rosemont, Montréal, Canada 27 16 Mater Private Clinic, Brisbane, Australia 28 29 17 Department of Nephrology, Faculty of Medicine and Dentistry, University of Alberta, 30 Edmonton, Alberta, Canada 31 18 Endocrine and Diabetes Unit, The Queen Elizabeth Hospital, Woodville, Australia 32 19 Garvan Institute of Medical Research, Sydney, Australia 33 20 Department of Medicine, University of Melbourne, Melbourne, Australia 34 21 Department of General Practice and Primary Health Care, University of Melbourne 35 22 Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), 36 37 Universidad Autonoma de Nuevo Leon, Monterrey 64460, Mexico 38 23 Evidence-based Medicine Research Center, Jiangxi University of Traditional Chinese 39 Medicine, Nanchang, China 40 24 Chinese Evidence-based Medicine Center and Cochrane China Center, West China Hospital, 41 Sichuan University, Chengdu, Sichuan, China 42 25 West China School of Medicine, Sichuan University, Chengdu, China 43 26 Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Sydney, 44 45 Australia 46 27 Department of Nephrology, Division of Medicine, McMaster University, Hamilton, Canada 47 48 49 50 Corresponding author: 51 52 Professor Giovanni FM Strippoli, MD PhD 53 Department of Emergency and Organ Transplantation 54 University of Bari 55 Piazza Giulio CESARE, 70124 56 57 Bari 58 Italy 59 [email protected] 60 2 https://mc.manuscriptcentral.com/bmj BMJ Page 4 of 244 1 2 3 Word count for text: 3684 4 5 Word count for abstract: 466 6 7 8 9 10 11 12 Confidential: For Review Only 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 3 https://mc.manuscriptcentral.com/bmj Page 5 of 244 BMJ 1 2 3 What is already known on this topic 4 5 6 Although trial results conflict, sodium glucose transporter 2 (SGLT-2) inhibitors and 7 8 glucagon-like peptide-1 (GLP-1) receptor agonists likely reduce cardiovascular and 9 10 kidney disease when added
Load more

Recommended publications
  • Pharmacokinetics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 Inhibitor
    Available online a t www.derpharmachemica.com ISSN 0975-413X Der Pharma Chemica, 2016, 8(12):292-295 CODEN (USA): PCHHAX (http://derpharmachemica.com/archive.html) Mini-review: Pharmacokinetics of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor Nermeen Ashoush a,b aClinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, British University in Egypt, El- Sherouk city, Cairo 11837, Egypt. bHead of Health Economics Unit, Center for Drug Research and Development (CDRD), Faculty of Pharmacy, British University in Egypt, El-Sherouk city, Cairo 11837, Egypt. _____________________________________________________________________________________________ ABSTRACT The dipeptidyl peptidase-4 (DPP-4) inhibitors are novel oral hypoglycemic drugs which have been in clinical use for the past 10 years. The drugs are safe, weight neutral and widely prescribed. There are currently many gliptins approved by FDA, namely sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin with several more in advanced stages of development. The gliptins may possess cardiovascular protective effects and their administration may promote β-cell survival; claims currently being evaluated in clinical and preclinical studies. The gliptins are an optional second-line therapy after metformin; they are generally well tolerated with low risk of hypoglycemia. The various compounds differ with respect to their pharmacokinetic properties; however, their clinical efficacy appears to be similar. The clinical differences between the various compounds
    [Show full text]
  • Renato Wilberto Zilli Eficácia Em Longo Prazo Das
    RENATO WILBERTO ZILLI EFICÁCIA EM LONGO PRAZO DAS GLIFLOZINAS VERSUS GLIPTINAS NO TRATAMENTO DO DIABETES MELLITUS TIPO 2 APÓS FALÊNCIA DA METFORMINA COMO MONOTERAPIA: REVISÃO SISTEMÁTICA E METANÁLISE EM REDE Tese apresentada ao Programa de Ciências Médicas da Faculdade de Medicina da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Processos Imunes e Infecciosos Orientador: Prof. Dr. Fabiano Pinheiro da Silva (Versão corrigida. Resolução CoPGr 6018/11, de 13 de outubro de 2011. A versão original está disponível na Biblioteca da FMUSP) São Paulo 2017 Dados Internacionais de Catalogação na Publicação (CIP) Preparada pela Biblioteca da Faculdade de Medicina da Universidade de São Paulo ©reprodução autorizada pelo autor Zilli, Renato Wilberto Eficácia em longo prazo das gliflozinas versus gliptinas no tratamento do diabetes mellitus tipo 2 após falência da metformina como monoterapia : revisão sistemática e metanálise em rede / Renato Wilberto Zilli ‐‐ São Paulo, 2017. Tese(doutorado)--Faculdade de Medicina da Universidade de São Paulo. Programa de Ciências Médicas. Área de concentração: Processos Imunes e Infecciosos. Orientador: Fabiano Pinheiro da Silva. Descritores: 1.Diabetes mellitus tipo 2 2.Metanálise 3.Terapia combinada 4.Falha de tratamento 5.Metformina 6.Inibidores da dipeptidil peptidase IV 7.Transportador 2 de glucose‐sódio/inibidores 8.Empagliflozina 9.Dapagliflozina 10.Saxagliptina USP/FM/DBD ‐302/17 Esta tese de doutorado está de acordo com as seguintes normas, em vigor no momento desta publicação: Referências: adaptado de International Committee of Medical Journals Editors (Vancouver). Guia de apresentação e dissertações, teses e monografias. Elaborado por Anneliese Cordeiro da Cunha, Maria Julia de A.L.
    [Show full text]
  • Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly
    2106 Diabetes Care Volume 38, November 2015 fi Wayne H.-H. Sheu,1 Ira Gantz,2 Safety and Ef cacy of Omarigliptin Menghui Chen,2 Shailaja Suryawanshi,2 Arpana Mirza,2 Barry J. Goldstein,2 (MK-3102), a Novel Once-Weekly Keith D. Kaufman,2 and Samuel S. Engel2 DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes Diabetes Care 2015;38:2106–2114 | DOI: 10.2337/dc15-0109 OBJECTIVE This study was conducted to determine the optimal dose of omarigliptin, a once- weekly (q.w.) dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of patients with type 2 diabetes and evaluate the long-term safety of that dose. RESEARCH DESIGN AND METHODS In a multicenter, double-blind, 12-week, dose-range finding study, 685 oral antihy- perglycemic agent-na¨ıve or washed-out subjects with type 2 diabetes were random- ized to one of five once-weekly doses of omarigliptin (0.25 mg, 1 mg, 3 mg, 10 mg, or 25 mg) or placebo. The primary efficacy end point was change from baseline in HbA1c, and secondary end points were 2-h postmeal glucose (PMG) and fasting plasma glucose (FPG). Analysis included all patients who received at least one dose of the study medication. Subjects who completed the base study were eligible to enter a 66-week extension study. RESULTS Once-weekly treatment for 12 weeks with omarigliptin provided dose-related reduc- 1Division of Endocrinology and Metabolism, De- partment of Internal Medicine, Taichung Veterans EMERGING TECHNOLOGIES AND THERAPEUTICS tions in HbA , 2-h PMG, and FPG.
    [Show full text]
  • Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis
    Online Supplementary Content Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. doi:10.1001/jama.2016.9400. eMethods. Summary of Statistical Analysis eTable 1. Search Strategies eTable 2. Description of Included Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 3. Description of Included Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 4. Description of Included Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin Plus Sulfonylurea eTable 5. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 6. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 7. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin plus Sulfonylurea eTable 8. Estimated Global Inconsistency in Networks of Outcomes eTable 9. Estimated Heterogeneity in Networks eTable 10. Definitions of Treatment Failure Outcome eTable 11. Contributions of Direct Evidence to the Networks of Treatments eTable 12. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes Given as Monotherapy eTable 13. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes When Used in Dual Therapy (in Addition to Metformin) eTable 14. Network Meta-analysis Estimates of Comparative Treatment Effects for Drug Classes Given as Triple Therapy eTable 15. Meta-regression Analyses for Drug Classes Given as Monotherapy (Compared With Metformin) eTable 16. Subgroup Analyses of Individual Sulfonylurea Drugs (as Monotherapy) on Hypoglycemia eTable 17.
    [Show full text]
  • Mastering the Outpatient Type 2 Management Objectives
    Jorge De Jesús MD Mastering the outpatient Type 2 Management Objectives: After this presentation you will be able to recognize: .Diabetes Mellitus is a progressive disease .Prevention is possible for selected high risk individuals • Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient- specific concerns, adverse drug reactions, and contraindications • Discuss the role and timing of combination therapy in achieving A1C goals • Explain the implications of recent, large randomized clinical trials on clinical decision-making • Modifications in 2019 ADA guidelines based on recent RCT trials Individualize Choose A1c goal 7% for most patients < 7% younger with few comorbidities Older group with multiple Comorbidities could be around 8% Glucose-lowering medication in type 2 diabetes: overall approach. American Diabetes Association Dia Care 2019;42:S90-S102 10: COST !!! ©2019 by American Diabetes Association Case 1: Carmen 55 year-old female with newly diagnosed type 2 diabetes Active: she takes care of her grandchildren while their mother works On physical examination , she is alert oriented Too busy to exercise. Eats the cooperative no acute distress same food as her grandchildren Height: 64” Weight 188# BMI=33 No alcohol BP=160/100 Foot Exam : normal pulses ; normal sensory Has hypertension and sleep apnea Fundoscopy , no retinopathy A1c=7.4%; creatinine .9 mg /dL; No history of pancreatitis, no no microalbuminuria; abnormal liver function, or CHF LDL=146
    [Show full text]
  • Official Protocol Title: NCT Number: NCT02906709 Document Date
    Official Protocol Title: A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy NCT number: NCT02906709 Document Date: 10-Mar-2017 Product: MK -3102 1 Protocol/Amendment No.: 039-01 THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., WHITEHOUSE STATION, NJ, U.S.A. SPONSOR: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the Sponsor or Merck) One Merck Drive P.O. Box 100 Whitehouse Station, New Jersey, 08889-0100, U.S.A. Protocol-specific Sponsor Contact information can be found in the Investigator Trial File Binder (or equivalent). TITLE: A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy EudraCT NUMBER: Not Applicable MK-3102-039-01 Final Protocol 10-Mar-2017 04MKJ4 Confidential Product: MK-3102 2 Protocol/Amendment No.: 039-01 TABLE OF CONTENTS SUMMARY OF CHANGES...............................................................................................
    [Show full text]
  • WO 2016/018931 Al 4 February 2016 (04.02.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/018931 Al 4 February 2016 (04.02.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/495 (2006.01) A61K 38/18 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 14/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 15/0425 10 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 28 July 2015 (28.07.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/03 1,063 30 July 2014 (30.07.2014) US kind of regional protection available): ARIPO (BW, GH, 62/195,908 23 July 2015 (23.07.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: NGM BIOPHARMACEUTICALS, INC.
    [Show full text]
  • Omarigliptin Decreases Inflammation and Insulin Resistance in A
    Hattori Diabetol Metab Syndr (2020) 12:24 https://doi.org/10.1186/s13098-020-00533-3 Diabetology & Metabolic Syndrome RESEARCH Open Access Omarigliptin decreases infammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes Sachiko Hattori* Abstract Background: Omarigliptin is a potent, selective, oral dipeptidyl peptidase 4 (DPP4) inhibitor with a half-life that allows weekly dosing. Infammation or insulin resistance might be pathological mediators of cardiovascular events in patients with type 2 diabetes. Methods: Whether omarigliptin has anti-infammatory efects that result in decreased levels of high-sensitivity C-reactive protein (hsCRP) and anti-insulin resistance efects that decrease levels of homeostatic model assessment of insulin resistance (HOMA-IR) were investigated. Patients were allocated to continue with daily DPP4 inhibitors (control, n 28) or to switch from daily DPP4 inhibitors to weekly omarigliptin (omarigliptin, n 56). Fasting blood and urine samples= were collected before, and every 3 months after intervention for 1 year. = Results: Omarigliptin tended to elicit reductions in fasting blood glucose (FBG), LDL-cholesterol, triglyceride, aspar- tate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), the urinary albumin-to-creatinine ratio (ACR) with logarithmic transformation (log ACR), and systolic and diastolic blood pressure, but the diferences did not reach statistical signifcance compared with control. Values for HDL-cholesterol tended to increase, but also did not reach statistical signifcance compared with control. Omarigliptin signifcantly decreased HOMA-IR, remnant-like particle cholesterol (RLP-C), and hsCRP with logarithmic transformation (log hsCRP) compared with control. However, omarigliptin did not afect hemoglobin A1c (HbA1c), body mass index (BMI), and estimated glomerular fltration rates (eGFR).
    [Show full text]
  • Pharmacy 482 Literature Review of Oral Treatment
    Med. Surg. J. – Rev. Med. Chir. Soc. Med. Nat., Iaşi – 2020 – vol. 124, no. 3 PHARMACY REVIEWS LITERATURE REVIEW OF ORAL TREATMENT OF TYPE 2 DIABETES MELLITUS Mousa Sha’at1, Cristina Mihaela Ghiciuc2, Alexandra Bujor1*, D. V. Timofte2, Alina Ștefanache1, Lăcrămioara Ochiuz1 “Grigore T. Popa” University of Medicine and Pharmacy Iasi 1. Faculty of Pharmacy 2. Faculty of Medicine *Corresponding author. E-mail: [email protected] LITERATURE REVIEW OF ORAL TREATMENT OF TYPE 2 DIABETES MELLITUS (Abstract): Type 2 non-insulin-dependent diabetes mellitus (T2DM), the most common form of diabetes that affects more than 90% of diabetic patients, is characterized by insulin re- sistance, β-pancreatic cells dysfunction, and increased hepatic glucose synthesis. The aim of the present paper was to review data on the efficacy of conventional oral dosage forms com- pared to controlled oral drug delivery systems for treating diabetes. Although the number of oral antidiabetic drugs has significantly increased in recent years, clinically there are still important limitations in terms of therapeutic efficacy, tolerability, and adverse effects, par- ticularly regarding weight gain and medium and long-term glucose control. The last genera- tion of oral pharmaceutical formulations such as modified-release tablets overcame some limitations, while injectable formulations with glucagon-like peptide-1 receptor agonists sig- nificantly increased the effectiveness of anti-diabetic medication and significantly reduced diabetes-specific comorbidities. Metformin extended-release formulation seems to be more effective than metformin conventional-release formulation in improving glyco-metabolic control, lipid profile, and levels of some adipocytokines in T2DM. Sustained-release glipiz- ide formulation increases the compliance compared to immediate-release glipizide because it seems to achieve similar glucose control with decreased insulin secretion and to decrease the frequency of hypoglycemic episodes.
    [Show full text]
  • Canagliflozin, Dapagliflozin and Empagliflozin Monotherapy for Treating Type 2 Diabetes: Systematic Review and Economic Evaluation
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 21 ISSUE 2 JANUARY 2017 ISSN 1366-5278 Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt and Norman Waugh DOI 10.3310/hta21020 Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation Rhona Johnston,1 Olalekan Uthman,2 Ewen Cummins,1 Christine Clar,3 Pamela Royle,2 Jill Colquitt,4 Bee Kang Tan,2 Andrew Clegg,5 Saran Shantikumar,2 Rachel Court,2 J Paul O’Hare,2 David McGrane,6 Tim Holt7 and Norman Waugh2* 1McMDC, Harrogate, UK 2Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK 3Berlin, Germany 4Effective Evidence, Waterlooville, UK 5University of Central Lancashire, Preston, UK 6Queen Elizabeth University Hospital, Glasgow, UK 7University of Oxford, Oxford, UK *Corresponding author Declared competing interests of authors: David McGrane has spoken at educational meetings sponsored by AstraZeneca, Eli Lilly, Sanofi, MSD, Takeda Pharmaceutical Company, Novo Nordisk, Janssen, and has served on Advisory Boards for Eli Lilly, Sanofi, Novo Nordisk. J Paul O’Hare has received lecture fees, advisory board meeting fees, and grants for research from Novo Nordisk and Sanofi. All fees are paid through University of Warwick to fund access to insulin projects in sub-Saharan Africa. Published January 2017 DOI: 10.3310/hta21020 This report should be referenced as follows: Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, et al.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]